Larimar Therapeutics, Inc.
NASDAQ:LRMR
Overview | Financials
Company Name | Larimar Therapeutics, Inc. |
Symbol | LRMR |
Currency | USD |
Price | 3.78 |
Market Cap | 241,188,948 |
Dividend Yield | 0% |
52-week-range | 3.01 - 13.68 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Carole S. Ben-Maimon M.D. |
Website | https://www.larimartx.com |
An error occurred while fetching data.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD